A perspective to weaponize microRNAs against lung cancer

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA, A Cancer Journal for Clinicians, 71, 209, 10.3322/caac.21660 Siegel, 2022, Cancer statistics, 2022, CA A Cancer J. Clin., 72, 7, 10.3322/caac.21708 Inamura, 2017, Lung cancer: understanding its molecular pathology and the 2015 WHO classification, Front. Oncol., 7, 193, 10.3389/fonc.2017.00193 Sun, 2020, Late-stage failures of monoclonal antibody drugs: a retrospective case study analysis, Pharmacology, 105, 145, 10.1159/000505379 A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum, D.H. Johnson, Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer, Http://Dx.Doi.Org/10.1056/NEJMoa061884. 355 (2009) 2542–2550. https://doi.org/10.1056/NEJMOA061884. Kurkjian, 2012, Risks and benefits with bevacizumab: evidence and clinical implications, Therapeutic Advances in Drug Safety, 3, 59, 10.1177/2042098611430109 Fecher, 2013, Ipilimumab and its toxicities: a multidisciplinary approach, Oncol., 18, 733, 10.1634/theoncologist.2012-0483 Wykosky, 2011, Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations, Chin. J. Cancer, 30, 5, 10.5732/cjc.010.10542 Wang, 2009, MicroRNA-based therapeutics for cancer, BioDrugs, 23, 15, 10.2165/00063030-200923010-00002 Fu, 2019, Recent progress in microRNA-based delivery systems for the treatment of human disease, ExRNA, 1 Liu, 2020, SELEX tool: a novel and convenient gel-based diffusion method for monitoring of aptamer-target binding, J. Biol. Eng., 14, 1, 10.1186/s13036-019-0223-y Lin, 2013, STAT3 upregulates miR-92a to inhibit RECK expression and to promote invasiveness of lung cancer cells, Br. J. Cancer, 109, 731, 10.1038/bjc.2013.349 Daugaard, 2017, miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells, Oncogenesis, 6, 10.1038/oncsis.2017.66 Wang, 2020, MiR-223 regulates autophagy associated with cisplatin resistance by targeting FBXW7 in human non-small cell lung cancer, Cancer Cell Int., 20, 1 Van Roosbroeck, 2016, Combining anti-miR-155 with chemotherapy for the treatment of lung cancers, Clin. Cancer Res., 23, 2891, 10.1158/1078-0432.CCR-16-1025 Salim, 2012, miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence, Br. J. Cancer, 1361, 10.1038/bjc.2012.382 Guo, 2017, MiR-30a radiosensitizes non-small cell lung cancer by targeting ATF1 that is involved in the phosphorylation of ATM, Oncol. Rep., 37, 1980, 10.3892/or.2017.5448 Zhao, 2011, The role of miR-506 in transformed 16HBE cells induced by anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide, Toxicol. Lett., 205, 320, 10.1016/j.toxlet.2011.06.022 Wu, 2016, miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9, Oncol. Lett., 11, 945, 10.3892/ol.2015.4000 Segal, 2020, Challenges identifying efficacious miRNA therapeutics for cancer, Expet Opin. Drug Deliv., 15, 987, 10.1080/17460441.2020.1765770 Zhang, 2015, Simultaneous delivery of therapeutic antagomirs with paclitaxel for the management of metastatic tumors by a pH-responsive anti-microbial peptide-mediated liposomal delivery system, J. Contr. Release : Official Journal of the Controlled Release Society, 197, 208, 10.1016/j.jconrel.2014.11.010 Wang, 2016, Imaging dendrimer-grafted graphene oxide mediated anti-miR-21 delivery with an activatable luciferase reporter, ACS Appl. Mater. Interfaces, 8, 9014, 10.1021/acsami.6b02662 Liu, 2013, Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development, Protein and Cell, 4, 932, 10.1007/s13238-013-3092-z Hindawi Guz, 2022, An insight into miR-1290: an oncogenic miRNA with diagnostic potential, Int. J. Mol. Sci., 23, 1234, 10.3390/ijms23031234 He, 2019, Exosomal miR-499a-5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma, Exp. Cell Res., 379, 203, 10.1016/j.yexcr.2019.03.035 Shi, 2012, Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells, Pharmaceut. Res., 29, 97, 10.1007/s11095-011-0514-6 Yung, 2016, Lipid nanoparticles composed of quaternary amine-tertiary amine cationic lipid combination (QTsome) for therapeutic delivery of AntimiR-21 for lung cancer, Mol. Pharm., 13, 653, 10.1021/acs.molpharmaceut.5b00878 Sriram, 2021, Calcium phosphate-polymeric nanoparticle system for co-delivery of microRNA-21 inhibitor and doxorubicin, Colloids Surf. B Biointerfaces, 208, 10.1016/j.colsurfb.2021.112061 Tian, 2015, Up-regulation of miR-21 expression predicate advanced clinicopathological features and poor prognosis in patients with non-small cell lung cancer, Pathol. Oncol. Res., 161 Shi, 2014, Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression, J. Contr. Release, 194, 228, 10.1016/j.jconrel.2014.09.005 Koeppen, 2021, Let-7b-5p in vesicles secreted by human airway cells reduces biofilm formation and increases antibiotic sensitivity of P. aeruginosa, Proc. Natl. Acad. Sci. U. S. A., 118, 10.1073/pnas.2105370118 Ahmad, 2013, Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs, J. Hematol. Oncol., 6, 77, 10.1186/1756-8722-6-77 Wang, 2015, Chemotherapy-induced miRNA-29c/Catenin-δ signaling suppresses metastasis in gastric cancer, Cancer Res., 75, 1332, 10.1158/0008-5472.CAN-14-0787 Farhan, 2019, Garcinol sensitizes NSCLC cells to standard therapies by regulating EMT-modulating miRNAs, Int. J. Mol. Sci., 20, E800, 10.3390/ijms20040800 Su, 2022, LINC00342 induces metastasis of lung adenocarcinoma by targeting miR-15b/TPBG, Acta Biochim. Pol., 69, 291 Arora, 2022, miR-16-5p regulates aerobic glycolysis and tumorigenesis of NSCLC cells via LDH-A/lactate/NF-κB signaling, Life Sci., 304, 10.1016/j.lfs.2022.120722 Feng, 2019, MiR-34b-3p represses cell proliferation, cell cycle progression and cell apoptosis in non-small-cell lung cancer (NSCLC) by targeting CDK4, J. Cell Mol. Med., 23, 5282, 10.1111/jcmm.14404 Lee, 2013, Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer, Int. J. Nanomed., 8, 4481 Esposito, 2014, Multifunctional aptamer-miRNA conjugates for targeted cancer therapy, Mol. Ther., 22, 1151, 10.1038/mt.2014.5 Dai, 2016, Combined delivery of let-7b MicroRNA and paclitaxel via biodegradable nanoassemblies for the treatment of KRAS mutant cancer, Mol. Pharm., 13, 520, 10.1021/acs.molpharmaceut.5b00756 Zhang, 2021, Pulmonary aerosol delivery of let-7b microRNA confers a striking inhibitory effect on lung carcinogenesis through targeting the tumor immune microenvironment, Adv. Sci., 8, 1 Jeong, 2020, Exosome-mediated microRNA-497 delivery for anti-cancer therapy in a microfluidic 3D lung cancer model, Lab Chip, 20, 548, 10.1039/C9LC00958B Wu, 2013, Therapeutic delivery of MicroRNA-29b by cationic lipoplexes for lung cancer, Mol. Ther. Nucleic Acids, 2, e84, 10.1038/mtna.2013.14 Perepelyuk, 2016, Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins, Int. J. Nanomed., 11, 3533, 10.2147/IJN.S110488 Perepelyuk, 2018, Evaluation of MUC1-aptamer functionalized hybrid nanoparticles for targeted delivery of miRNA-29b to nonsmall cell lung cancer, Mol. Pharm., 15, 985, 10.1021/acs.molpharmaceut.7b00900 Magalhães, 2020, miR-29b and retinoic acid co-delivery: a promising tool to induce a synergistic antitumoral effect in non-small cell lung cancer cells, Drug Deliv. Transl. Res., 10, 1367, 10.1007/s13346-020-00768-7 Xing, 2021, N-Isopropylacrylamide-modified polyethylenimine-mediated miR-29a delivery to inhibit the proliferation and migration of lung cancer cells, Colloids Surf. B Biointerfaces, 198, 10.1016/j.colsurfb.2020.111463 Chen, 2010, Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy, Mol. Ther., 18, 1650, 10.1038/mt.2010.136 Trang, 2011, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice, Mol. Ther., 19, 1116, 10.1038/mt.2011.48 Xue, 2014, Small RNA combination therapy for lung cancer, vol. 111, 3553 Gu, 2017, A combination RNAi-chemotherapy layer-by-layer nanoparticle for systemic targeting of KRAS/P53 with cisplatin to treat non–small cell lung cancer, Clin. Cancer Res., 23, 7312, 10.1158/1078-0432.CCR-16-2186 Trivedi, 2017, MicroRNA-34a encapsulated in hyaluronic acid nanoparticles induces epigenetic changes with altered mitochondrial bioenergetics and apoptosis in non-small-cell lung cancer cells, Sci. Rep., 7, 1, 10.1038/s41598-017-02816-8 Orellana, 2017, FolamiRs: ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer, Sci. Transl. Med., 9, 10.1126/scitranslmed.aam9327 Shi, 2014, The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells, PLoS One, 9 Meng, 2019, Ultrasound-microbubbles-mediated microRNA-449a inhibits lung cancer cell growth via the regulation of notch1, OncoTargets Ther., 12, 7437, 10.2147/OTT.S217021 Iaboni, 2016, Aptamer-miRNA-212 conjugate sensitizes NSCLC cells to TRAIL, Mol. Ther. Nucleic Acids, 5, e289, 10.1038/mtna.2016.5 D'Almeida, 2019, Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells, BMC Cancer, 19, 1 Peng, 2016, Electroneutral composite polymersomes self-assembled by amphiphilic polyphosphazenes for effective miR-200c in vivo delivery to inhibit drug resistant lung cancer, Biomaterials, 106, 1, 10.1016/j.biomaterials.2016.08.001 Wu, 2011, MicroRNA delivery by cationic lipoplexes for lung cancer therapy, Mol. Pharm., 8, 1381, 10.1021/mp2002076 Jiang, 2019, Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo, J. Cancer Res. Clin. Oncol., 145, 2951, 10.1007/s00432-019-03051-6 Moro, 2019, Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models, J. Contr. Release, 308, 44, 10.1016/j.jconrel.2019.07.006 Peng, 2021, Delivery of miR-320a-3p by gold nanoparticles combined with photothermal therapy for directly targeting Sp1 in lung cancer, Biomater. Sci., 9, 6528, 10.1039/D1BM01124C Lee, 2016, Biogenesis and regulation of the let-7 miRNAs and their functional implications, Protein & Cell, 7, 100, 10.1007/s13238-015-0212-y Barh, 2010, Microrna let-7: an emerging next-generation cancer therapeutic, Curr. Oncol., 17, 70, 10.3747/co.v17i1.356 Aqeilan, 2009, miR-15a and miR-16-1 in cancer: discovery, function and future perspectives, Cell Death Differ., 215 Reid, 2013, Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma, Ann. Oncol., 24, 3128, 10.1093/annonc/mdt412 Jiang, 2014, Diverse roles of miR-29 in cancer, Oncol. Rep., 31, 1509, 10.3892/or.2014.3036 Fabbri, 2007, MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B, Proc. Natl. Acad. Sci. USA, 104, 15805, 10.1073/pnas.0707628104 Teneng, 2014, Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer, Oncogene, 621 Munkhbaatar, 2020, MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically, Nat. Commun., 1 Connolly, 2013, Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment, Clin. Cancer Res., 19, 1651, 10.1158/1078-0432.CCR-12-3175 Zhang, 2019, MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer, J. Exp. Clin. Cancer Res., 38, 1 Daugaard, 2017, The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma, Exp. Mol. Pathol., 102, 484, 10.1016/j.yexmp.2017.05.012 Bou Kheir, 2011, miR-449 inhibits cell proliferation and is down-regulated in gastric cancer, Mol. Cancer, 10, 1, 10.1186/1476-4598-10-29 Wang, 2015, Aptamer-dendrimer bioconjugates for targeted delivery of miR-34a expressing plasmid and antitumor effects in non-small cell lung cancer cells, PLoS One, 10, 1 Lv, 2017, MiR-212-5p suppresses the epithelial-mesenchymal transition in triple-negative breast cancer by targeting Prrx2, Cell. Physiol. Biochem., 44, 1785, 10.1159/000485785 Li, 2015, miR-132 inhibits lung cancer cell migration and invasion by targeting SOX4, J. Thorac. Dis., 7, 1563 Chen, 2019, MicroRNA-212 suppresses nonsmall lung cancer invasion and migration by regulating ubiquitin-specific protease-9, J. Cell. Biochem., 120, 6482, 10.1002/jcb.27939 Nuzzo, 2019, Axl-targeted delivery of the oncosuppressor miR-137 in non-small-cell lung cancer, Mol. Ther. Nucleic Acids, 17, 256, 10.1016/j.omtn.2019.06.002 Xue, 2021, miR-200 deficiency promotes lung cancer metastasis by activating Notch signaling in cancer-associated fibroblasts, Genes Dev., 35, 1109, 10.1101/gad.347344.120 Roybal, 2011, miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting flt1/VEGFR1, Mol. Cancer Res., 9, 25, 10.1158/1541-7786.MCR-10-0497 Moll, 2003, The MDM2-p53 interaction, Mol. Cancer Res., 1, 1001 Han, 2019, Nucleobase-modified polyamidoamine-mediated mir-23b delivery to inhibit the proliferation and migration of lung cancer, Trans. Ann. Meet. Soc. Biomater. Ann. Int. Biomater. Symp., 40, 581 Chiou, 2012, Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma, J. Contr. Release, 159, 240, 10.1016/j.jconrel.2012.01.014 Hanna, 2019, The potential for microRNA therapeutics and clinical research, Front. Genet., 10, 478, 10.3389/fgene.2019.00478 Hong, 2020, Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours, Br. J. Cancer, 1630, 10.1038/s41416-020-0802-1 van Zandwijk, 2017, Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study, Lancet Oncol., 18, 1386, 10.1016/S1470-2045(17)30621-6